NASDAQ: HROW · Life Sciences · 4 alerts · CIK 1360214
Share price
$29.09Close, Nov 16
Market cap
$1.09B
Shares outstanding
37.53MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Harrow, Inc. filings on SEC EDGAR ↗
Harrow, Inc. filed a formal corporate presentation to be used by management at the Jefferies Global Healthcare Conference in London. The presentation highlights the company's ophthalmic pharmaceutical portfolio, including core growth brands VEVYE, IHEEZO, and TRIESENCE. The filing is a standard Regulation FD disclosure to provide the investment community with updated strategic and commercial information.
Harrow, Inc. reported a significant revenue increase to $99.3 million for Q3 2026, up from $71.6 million in the prior year, though it faced a net loss of $35.1 million for the first nine months of 2026. The company strengthened its liquidity through $49 million in net proceeds from notes payable, ending the period with $75.3 million in cash and cash equivalents.
Harrow reported record third-quarter 2026 revenue of $99.3 million, a 39% increase year-over-year, driven by strong performance in branded products like VEVYE and TRIESENCE. The company reaffirmed its full-year 2026 revenue guidance of $350 million to $365 million but lowered its Adjusted EBITDA outlook to more than $40 million to account for first-half shortfalls and increased R&D spending.
Term
Q3 2026
“The third quarter delivered the second-half acceleration we anticipated. Branded products drove record revenue, growing 62% year over year. VEVYE delivered record quarterly revenue, supported by continued prescription growth, improving economics, and increasing productivity from our expanded sales force.”
Mark L. Baum, Chairman and Chief Executive Officer of Harrow
“We expect the fourth quarter to be Harrow’s strongest on record and that second-half revenue will exceed the high end of what we contemplated in March. That said, our updated Adjusted EBITDA outlook reflects both the first half operating shortfall against our original plan and additional spending to accelerate our G-MELT NDA submission, advance important development programs, and integrate TYRVAYA.”
Mark L. Baum, Chairman and Chief Executive Officer of Harrow